ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

VTRS Viatris Inc

11.57
-0.21 (-1.78%)
30 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Viatris Inc VTRS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.21 -1.78% 11.57 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
11.74 11.57 11.75 11.57 11.78
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
16/4/202415:30PRNUSViatris to Report First Quarter 2024 Financial Results on..
15/4/202407:00PRNUSViatris Appoints Corinne Le Goff as Chief Commercial Officer
15/4/202405:59PRNCAViatris Announces Launch of First Bioequivalent Generic..
01/4/202405:59PRNUSViatris Announces the Launch of RYZUMVl™ (Phentolamine..
27/3/202405:59PRNUSViatris Hosts R&D Event Focusing on its Collaboration with..
05/3/202419:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:26EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/3/202417:11EDGAR2Form 144 - Report of proposed sale of securities
28/2/202406:39EDGAR2Form 8-K - Current report
28/2/202405:30PRNUSViatris Reports Fourth-Quarter and Full-Year 2023 Financial..
28/2/202400:00PRNUSViatris and Idorsia Enter Into Significant Global Research..
23/2/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202416:18EDGAR2Form 144 - Report of proposed sale of securities
05/2/202405:59PRNUSViatris to Announce Fourth Quarter and Full-Year 2023..
30/1/202415:40EDGAR2Form 8-K/A - Current report: [Amend]
19/1/202405:56PRNUSViatris recognised as a Top Employer 2024 in the UK for the..
05/1/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202419:28EDGAR2Form 144 - Report of proposed sale of securities
21/12/202315:05PRNUSViatris to Participate in 42nd Annual J.P. Morgan Healthcare..
15/12/202317:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202316:04EDGAR2Form 8-K/A - Current report: [Amend]
15/12/202316:00EDGAR2Form 8-K - Current report
15/12/202315:45PRNUSViatris Continues its Preparations for Phase 2 of its..
15/12/202315:14EDGAR2Form 8-K - Current report
15/12/202315:12EDGAR2Form 8-K - Current report
15/12/202315:05PRNUSViatris Shareholders Re-elect All Nominated Directors and..
14/12/202316:31EDGAR2Form 144 - Report of proposed sale of securities
24/11/202317:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/11/202315:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24/11/202312:02EDGAR2Form 144 - Report of proposed sale of securities
14/11/202307:00PRNUSViatris to Participate in the Jefferies London Healthcare..
13/11/202307:00PRNUSViatris and Theravance Biopharma Announce Positive Top-Line..
07/11/202315:39EDGAR2Form 8-K - Current report
07/11/202315:02PRNUSViatris Reports Strong Financial and Operational Results for..
03/11/202315:36EDGAR2Form ARS - Annual Report to Security Holders
03/11/202315:33EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
03/11/202315:31EDGAR2Form DEF 14A - Other definitive proxy statements
30/10/202308:00PRNUSViatris to Host Webinar: The Power of Partnership to Address..
24/10/202315:32EDGAR2Form 8-K - Current report
24/10/202315:30EDGAR2Form PRE 14A - Other preliminary proxy statements
23/10/202308:00PRNUSViatris Named to Forbes' Annual List of the World's Best..
20/10/202316:18EDGAR2Form 8-K - Current report
20/10/202316:00PRNUSRajiv Malik to Retire as President of Viatris Effective..
18/10/202307:00PRNUSViatris Named to 3BL's 100 Best Corporate Citizens of 2023..
10/10/202308:29PRNUSViatris to Release Third Quarter 2023 Financial Results on..

Su Consulta Reciente

Delayed Upgrade Clock